Abstract
Inhibition of the β-secretase, BACE1, which cleaves amyloid precursor protein (APP) to produce β-amyloid protein (Aβ), is thought to be a feasible therapeutic strategy for Alzheimer’s disease. Reticulon (RTN) proteins such as RTN3 have been identified as membrane proteins that interact with BACE1 and inhibit its Aβ-generating activity. In this study, we investigated whether RTN3 can regulate Aβ production in vivo, using transgenic (Tg) mice expressing APP with Swedish and London mutations (APP Tg mice) and those expressing RTN3; the latter mice showed ~1.4-fold higher expression levels of RTN3 protein in the cerebral cortex than non-Tg controls. We analyzed the brains of single APP Tg and double APP/RTN3 Tg mice at the age of approximately 15 months. The levels of secreted APP-β, a direct BACE1 cleavage product of APP, in Tris-soluble fraction were considerably reduced in the hippocampus and cerebral cortex of APP/RTN3 Tg mice relative to those in APP Tg mice. Immunohistochemical analyses demonstrated that Aβ burden and plaques were significantly (by approximately 50%) decreased in both the hippocampus and cerebral cortex of double Tg mice compared to APP Tg mice. Furthermore, the levels of guanidine-soluble Aβ40 and Aβ42 in these brain regions of APP/RTN3 Tg mice were relatively lower than those in APP Tg mice. These findings indicate that even a small increase in RTN3 expression exerts suppressive effects on amyloidogenic processing of APP and Aβ accumulation through modulation of BACE1 activity in vivo, and suggest that induction of RTN3 might be an effective therapeutic strategy against Alzheimer’s disease.
Keywords: Alzheimer’s disease, β-amyloid, β-secretase, BACE1, reticulon; transgenic mice
Current Alzheimer Research
Title:Reduction of β-Amyloid Accumulation by Reticulon 3 in Transgenic Mice
Volume: 10 Issue: 2
Author(s): Wataru Araki, Akiko Oda, Kazumi Motoki, Kotaro Hattori, Masayuki Itoh, Shigeki Yuasa, Yoshihiro Konishi, Ryong-Woon Shin, Akira Tamaoka and Koichi Ogino
Affiliation:
Keywords: Alzheimer’s disease, β-amyloid, β-secretase, BACE1, reticulon; transgenic mice
Abstract: Inhibition of the β-secretase, BACE1, which cleaves amyloid precursor protein (APP) to produce β-amyloid protein (Aβ), is thought to be a feasible therapeutic strategy for Alzheimer’s disease. Reticulon (RTN) proteins such as RTN3 have been identified as membrane proteins that interact with BACE1 and inhibit its Aβ-generating activity. In this study, we investigated whether RTN3 can regulate Aβ production in vivo, using transgenic (Tg) mice expressing APP with Swedish and London mutations (APP Tg mice) and those expressing RTN3; the latter mice showed ~1.4-fold higher expression levels of RTN3 protein in the cerebral cortex than non-Tg controls. We analyzed the brains of single APP Tg and double APP/RTN3 Tg mice at the age of approximately 15 months. The levels of secreted APP-β, a direct BACE1 cleavage product of APP, in Tris-soluble fraction were considerably reduced in the hippocampus and cerebral cortex of APP/RTN3 Tg mice relative to those in APP Tg mice. Immunohistochemical analyses demonstrated that Aβ burden and plaques were significantly (by approximately 50%) decreased in both the hippocampus and cerebral cortex of double Tg mice compared to APP Tg mice. Furthermore, the levels of guanidine-soluble Aβ40 and Aβ42 in these brain regions of APP/RTN3 Tg mice were relatively lower than those in APP Tg mice. These findings indicate that even a small increase in RTN3 expression exerts suppressive effects on amyloidogenic processing of APP and Aβ accumulation through modulation of BACE1 activity in vivo, and suggest that induction of RTN3 might be an effective therapeutic strategy against Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Araki Wataru, Oda Akiko, Motoki Kazumi, Hattori Kotaro, Itoh Masayuki, Yuasa Shigeki, Konishi Yoshihiro, Shin Ryong-Woon, Tamaoka Akira and Ogino Koichi, Reduction of β-Amyloid Accumulation by Reticulon 3 in Transgenic Mice, Current Alzheimer Research 2013; 10 (2) . https://dx.doi.org/10.2174/1567205011310020003
DOI https://dx.doi.org/10.2174/1567205011310020003 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging
The thematic issue, Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging, aims to bridge the gap between advanced computational techniques and clinical practice in Alzheimer’s disease research. Alzheimer’s disease poses significant challenges in early diagnosis, disease progression monitoring, and predicting treatment efficacy. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Recent Insights on the Pro-Apoptotic Phenotype Elicited by Presenilin 2 and its Caspase and Presenilinase-Derived Fragments
Current Alzheimer Research New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology Neurogenesis and Alzheimers Disease: Biology and Pathophysiology in Mice and Men
Current Alzheimer Research The Chiptip: A Novel Tool for Automated Patch Clamp
Combinatorial Chemistry & High Throughput Screening 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice
Current Alzheimer Research Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets Gene Therapy for Chronic Traumatic Brain Injury: Challenges in Resolving Long-term Consequences of Brain Damage
Current Gene Therapy Entrainment of the Human Circadian Clock to the Light-Dark Cycle and its Impact on Patients in the ICU and Nursing Home Settings
Current Pharmaceutical Design Smart Community Care System: Ambient Intelligence Using Radio Frequency Identification (RFID) and Mobile Agent
Recent Patents on Computer Science Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Electrochemical Determination of Rivastigmine Hydrogen Tartrate at β-Cyclodextrin/Multi-Walled Carbon Nanotubes Modified Electrode
Current Pharmaceutical Analysis Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets
CNS & Neurological Disorders - Drug Targets The Action of Polyphenols in Diabetes Mellitus and Alzheimer's Disease: A Common Agent for Overlapping Pathologies
Current Neuropharmacology There is no Failure, Only Discovery—the Year Ahead for CARving New Paths
Current Alzheimer Research Multi-potent Natural Scaffolds Targeting Amyloid Cascade: In Search of Alzheimer's Disease Therapeutics
Current Topics in Medicinal Chemistry Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer’s disease
CNS & Neurological Disorders - Drug Targets Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets The Antiepileptic Potential of Nucleosides
Current Medicinal Chemistry